GUFICBIOGufic Biosciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 22.8% YoY
- • Profit growth: 183.1% YoY
- • Debt/Equity: 0.61
- • RSI: 52
- • Price vs EMA21: above
- • Price vs SMA50: above
- • Pullback to 21-EMA signal (setup quality 74%)
Bull case
- • Revenue growth: 22.8% YoY
- • Profit growth: 183.1% YoY
- • Debt/Equity: 0.61
- • RSI: 52
Bear case
- • ROE: 10.1%
- • Valuation vs sector: P/E 66.3 vs sector 40.5
- • MACD: bearish
- • Volume: 0.6x 20-day average
Key risks
- • ROE: 10.1%
- • Valuation vs sector: P/E 66.3 vs sector 40.5
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹17.12). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.